|
|
Article: Other News To Note.(Company overview)
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
p class=text>
o Aastrom Biosciences Inc., of Ann Arbor, Mich., received a Phase I Small Business Innovation Research grant from the National Cancer Institute in Bethesda, Md., to develop an immunotherapeutic treatment for malignant melanoma using its AastromReplicell System. The $124,000, eight-month study is designed to demonstrate the feasibility and advantages of using Aastrom's technology to expand T lymphocytes from patients' tumors or peripheral blood to treat malignant melanoma.
o Adenosine Therapeutics LLC, of Charlottesville, Va., reported the award of a Phase II Small Business Innovation Research grant from the National Institutes of Health. ...